Eli Lilly (LLY)
International Stocks
Buy
The analyst evaluates Eli Lilly's leadership position in the pharmaceutical sector and its financial growth metrics.
Unknown5h
* Does not constitute investment advice
Yükleniyor...
Yükleniyor...
How recommendation distribution changed over time
Covered by 5 analysts
Analysts are largely in agreement
Evaluated within the last 7 days
One-directional consensus
Stable interest level
Chronological view of analyst recommendations for this asset
The speaker analyzes the impact of GLP-1 agonists on market data and how these drugs are fundamentally transforming consumer behavior.
CNBC TelevisionThe speaker scrutinizes growth dynamics in the pharmaceutical sector, the market share potential of next-generation treatments, and margin structures.
CNBC TelevisionThe speaker scrutinizes new drug approval processes and market potential in the biotechnology sector.
Meet KevinThe speaker analyzes Eli Lilly's drug portfolio, next-generation compounds, and the impact of clinical trial data on the competitive landscape.
CNBC TelevisionThe speaker examines the competitor's market share dynamics in the sector, the impact of dosage differences on efficacy, and the competitive outlook.
CNBC TelevisionThe speaker examines the company's direct-to-consumer strategies and potential collaborations with compliant platforms within the context of its competition with Novo Nordisk.
CNBC TelevisionThe pharmaceutical company's expansion into new treatment areas and strong performance expectations are evaluated.
CNBC TelevisionGuggenheim Managing Director Seamus Fernandez evaluates Eli Lilly's market position, noting a strong patient and physician preference for its weight loss drugs, Mounjaro and Zepbound. He further analyzes the company's accelerating pipeline and robust patent estate, which contribute to its leadership in the GLP-1 market.
CNBC TelevisionEli Lilly announced a highly positive financial forecast for the year, projecting substantial sales growth driven by its leading obesity medications. The discussion highlights the immediate strong market reaction, with shares significantly increasing on the optimistic outlook.
Yahoo FinanceThe speaker examines Eli Lilly's upcoming earnings, focusing on the balance between predictable pricing and uncertain volumes, and the potential impact of new weight-loss treatments on margins.
Yahoo FinanceThe speaker evaluates Eli Lilly as a favored growth stock in the pharmaceutical sector, highlighting its potential despite industry-wide challenges like patent expirations. The company's market position is analyzed ahead of its upcoming earnings report.
CNBC TelevisionThe speaker evaluates the potential impact of upcoming clinical trial reports on stock performance and the decisive role of new data rather than earnings reports.
CNBC TelevisionThe speaker examines the high-tech AI collaboration aimed at accelerating drug discovery processes and expanding the total addressable market.
Yahoo FinanceThe speaker analyzes the strategic shift in pharmaceutical R&D budgets towards artificial intelligence infrastructure.
CNBC-eThe speaker evaluates the pharmaceutical sector's transition to AI usage in R&D processes and the impact of this transformation on efficiency.
Yahoo FinanceThe speaker analyzes the AI-driven R&D transformation and budget shifts in the pharmaceutical sector.
Yahoo FinanceThe speaker analyzes the competitive landscape in the pharmaceutical sector and regulatory risks on pricing alongside the fundamental growth story.
CNBC TelevisionThe speaker analyzes the performance expectations of major pharmaceutical firms in the current economic cycle.
CNBC TelevisionThe speaker positions this company as the benchmark at the top of the sector in his healthcare industry analysis.
CNBC TelevisionThe analyst evaluates Eli Lilly's leadership position in the pharmaceutical sector and its financial growth metrics.
* Does not constitute investment advice
The speaker analyzes the impact of GLP-1 agonists on market data and how these drugs are fundamentally transforming consumer behavior.
* Does not constitute investment advice
The speaker scrutinizes growth dynamics in the pharmaceutical sector, the market share potential of next-generation treatments, and margin structures.
* Does not constitute investment advice
The speaker scrutinizes new drug approval processes and market potential in the biotechnology sector.
* Does not constitute investment advice
The speaker analyzes Eli Lilly's drug portfolio, next-generation compounds, and the impact of clinical trial data on the competitive landscape.
* Does not constitute investment advice
The speaker examines the competitor's market share dynamics in the sector, the impact of dosage differences on efficacy, and the competitive outlook.
* Does not constitute investment advice
The speaker examines the company's direct-to-consumer strategies and potential collaborations with compliant platforms within the context of its competition with Novo Nordisk.
* Does not constitute investment advice
The pharmaceutical company's expansion into new treatment areas and strong performance expectations are evaluated.
* Does not constitute investment advice
Guggenheim Managing Director Seamus Fernandez evaluates Eli Lilly's market position, noting a strong patient and physician preference for its weight loss drugs, Mounjaro and Zepbound. He further analyzes the company's accelerating pipeline and robust patent estate, which contribute to its leadership in the GLP-1 market.
* Does not constitute investment advice
Eli Lilly announced a highly positive financial forecast for the year, projecting substantial sales growth driven by its leading obesity medications. The discussion highlights the immediate strong market reaction, with shares significantly increasing on the optimistic outlook.
* Does not constitute investment advice
The speaker examines Eli Lilly's upcoming earnings, focusing on the balance between predictable pricing and uncertain volumes, and the potential impact of new weight-loss treatments on margins.
* Does not constitute investment advice
The speaker evaluates Eli Lilly as a favored growth stock in the pharmaceutical sector, highlighting its potential despite industry-wide challenges like patent expirations. The company's market position is analyzed ahead of its upcoming earnings report.
* Does not constitute investment advice
The speaker evaluates the potential impact of upcoming clinical trial reports on stock performance and the decisive role of new data rather than earnings reports.
* Does not constitute investment advice
The speaker examines the high-tech AI collaboration aimed at accelerating drug discovery processes and expanding the total addressable market.
* Does not constitute investment advice
The speaker analyzes the strategic shift in pharmaceutical R&D budgets towards artificial intelligence infrastructure.
* Does not constitute investment advice
The speaker evaluates the pharmaceutical sector's transition to AI usage in R&D processes and the impact of this transformation on efficiency.
* Does not constitute investment advice
The speaker analyzes the AI-driven R&D transformation and budget shifts in the pharmaceutical sector.
* Does not constitute investment advice
The speaker analyzes the competitive landscape in the pharmaceutical sector and regulatory risks on pricing alongside the fundamental growth story.
* Does not constitute investment advice
The speaker analyzes the performance expectations of major pharmaceutical firms in the current economic cycle.
* Does not constitute investment advice
The speaker positions this company as the benchmark at the top of the sector in his healthcare industry analysis.
* Does not constitute investment advice